CA2795753A1 - Nouvel inhibiteur galactoside de galectines - Google Patents

Nouvel inhibiteur galactoside de galectines Download PDF

Info

Publication number
CA2795753A1
CA2795753A1 CA2795753A CA2795753A CA2795753A1 CA 2795753 A1 CA2795753 A1 CA 2795753A1 CA 2795753 A CA2795753 A CA 2795753A CA 2795753 A CA2795753 A CA 2795753A CA 2795753 A1 CA2795753 A1 CA 2795753A1
Authority
CA
Canada
Prior art keywords
galectin
level
pulmonary fibrosis
compound
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2795753A
Other languages
English (en)
Inventor
Neil Henderson
Tariq Sethi
Alison Mackinnon
Hakon Leffler
Ulf Nilsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galecto Biotech AB
Original Assignee
University of Edinburgh
Galecto Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh, Galecto Biotech AB filed Critical University of Edinburgh
Priority to CA2795753A priority Critical patent/CA2795753A1/fr
Priority to ES13785446T priority patent/ES2817888T3/es
Priority to IN2573DEN2015 priority patent/IN2015DN02573A/en
Priority to PCT/EP2013/072691 priority patent/WO2014067986A1/fr
Priority to CN201380057194.2A priority patent/CN104755088A/zh
Priority to CA2884802A priority patent/CA2884802A1/fr
Priority to EP17183955.8A priority patent/EP3278805A1/fr
Priority to EP13785446.9A priority patent/EP2914269B1/fr
Priority to JP2015538502A priority patent/JP2015535233A/ja
Publication of CA2795753A1 publication Critical patent/CA2795753A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2795753A 2012-10-31 2012-11-15 Nouvel inhibiteur galactoside de galectines Abandoned CA2795753A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2795753A CA2795753A1 (fr) 2012-10-31 2012-11-15 Nouvel inhibiteur galactoside de galectines
ES13785446T ES2817888T3 (es) 2012-10-31 2013-10-30 Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar
IN2573DEN2015 IN2015DN02573A (fr) 2012-10-31 2013-10-30
PCT/EP2013/072691 WO2014067986A1 (fr) 2012-10-31 2013-10-30 Galactoside inhibiteur de la galectine-3 et son utilisation pour le traitement de la fibrose pulmonaire
CN201380057194.2A CN104755088A (zh) 2012-10-31 2013-10-30 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
CA2884802A CA2884802A1 (fr) 2012-10-31 2013-10-30 Galactoside inhibiteur de la galectine-3 et son utilisation pour le traitement de la fibrose pulmonaire
EP17183955.8A EP3278805A1 (fr) 2012-10-31 2013-10-30 Diagnostic de la fibrose pulmonaire
EP13785446.9A EP2914269B1 (fr) 2012-10-31 2013-10-30 Galactoside inhibiteur du galectine-3 et son utilisation pour traiter la fibrose pulmonaire
JP2015538502A JP2015535233A (ja) 2012-10-31 2013-10-30 ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2794066A CA2794066C (fr) 2012-10-31 2012-10-31 Inhibiteur de la galactoside des galactines
CA2,794,066 2012-10-31
CA2795753A CA2795753A1 (fr) 2012-10-31 2012-11-15 Nouvel inhibiteur galactoside de galectines

Publications (1)

Publication Number Publication Date
CA2795753A1 true CA2795753A1 (fr) 2014-04-30

Family

ID=50605933

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2794066A Active CA2794066C (fr) 2011-04-19 2012-10-31 Inhibiteur de la galactoside des galactines
CA2795753A Abandoned CA2795753A1 (fr) 2012-10-31 2012-11-15 Nouvel inhibiteur galactoside de galectines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2794066A Active CA2794066C (fr) 2011-04-19 2012-10-31 Inhibiteur de la galactoside des galactines

Country Status (1)

Country Link
CA (2) CA2794066C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018067693A2 (pt) * 2016-03-04 2019-01-08 Galectin Sciences Llc compostos de selenogalactosídeo para a prevenção e tratamento de doenças associadas com galectina e usos dos mesmos
WO2018209255A1 (fr) 2017-05-12 2018-11-15 Galectin Sciences, Llc Composés pour la prévention et le traitement de maladies et leur utilisation

Also Published As

Publication number Publication date
CA2794066C (fr) 2017-02-28
CA2794066A1 (fr) 2014-04-30

Similar Documents

Publication Publication Date Title
US20210221836A1 (en) Idiopathic pulmonary fibrosis-detection, monitoring, prediction methods
EP2914269B1 (fr) Galactoside inhibiteur du galectine-3 et son utilisation pour traiter la fibrose pulmonaire
Bolaños et al. Role of Sonic Hedgehog in idiopathic pulmonary fibrosis
Sun et al. Sphingosine-1–phosphate receptor–3 is a novel biomarker in acute lung injury
US7238715B2 (en) Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US8178091B2 (en) Compositions and methods for the treatment of respiratory disorders
Sousa et al. Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium.
US20120021924A1 (en) Detection and modulation of cytochrome c acetylation
JP2017507322A (ja) ヒトペリオスチンを検出する新規アッセイ
CA2795753A1 (fr) Nouvel inhibiteur galactoside de galectines
Tokunaga et al. The significance of CD163-expressing macrophages in asthma
Manohar et al. Proteomic identification and analysis of human endometrial proteins associated with unexplained infertility
JP6712235B2 (ja) 肺癌のためのバイオマーカー、その診断方法、およびキット
KR100756972B1 (ko) 만성폐쇄성폐질환의 예방, 치료 및 진단용 조성물 및 방법
JP2022551649A (ja) 移植片対宿主病のバイオマーカー
WO2019064073A1 (fr) Utilisation de ca125 pour prédire le traitement anti-mésothéline de mésothéliomes
Øie et al. Adrenomedullin is increased in alveolar macrophages and released from the lungs into the circulation in severe heart failure
US20230078511A1 (en) Methods of using momelotinib to treat joint inflammation
Potapov cand. med. science, as. prof. Dnipro State Medical University, Ukraine
KR100733695B1 (ko) 만성염증성기도질환의 예방, 치료 및 진단용 조성물
TW202406543A (zh) Pde4抑制劑臨床反應之預測性生物標記
WO2024038185A1 (fr) Procédé de sélection de patients pour le traitement avec un antagoniste de l'axe d'il-33
WO2024027901A1 (fr) Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4
Xia et al. Upregulation of plasma SOCS-3 is associated with poor prognosis of acute myocardial ingarction
Shetty Articles in PresS. Am J Physiol Lung Cell Mol Physiol (January 8, 2016). doi: 10.1152/ajplung. 00290.2015

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170627

FZDE Dead

Effective date: 20200106